在耐火性非传染性前额膜炎中使用secukinumab
Otto M Olivas-Vergara1, Inés Hernanz2, Pablo E Borges-Deniz1
1Rheumatology Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
Frontiers in ophthalmology
|March 14, 2025
概括
对于其他炎症状况的治疗方法secukinumab,在耐火性前膜炎的患者中没有预防发作. 需要进一步的研究来澄清它在治疗这种特定眼睛疾病中的作用.
科学领域:
- 眼科医生 眼科 眼科
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
背景情况:
- 塞库金纽马布准了17A型联列素,在牛皮性关节炎,牛皮和轴性脊柱关节炎中显示出有效性.
- 它在非先前的非传染性脑膜炎中的有效性是有争议的,支持证据有限.
- 在前部非传染性脑膜炎中,secukinumab的治疗作用在很大程度上仍未确定.
研究的目的:
- 为了研究secukinumab在患有生物疗法耐药性非传染性前性脑膜炎的患者中的疗效.
主要方法:
- 采用了一个案例系列设计.
- 五名被诊断患有耐火性非传染性前膜炎的患者接受了secukinumab治疗.
主要成果:
- 所有五名患者都经历了膜炎的爆发,尽管接受了secukinumab治疗.
- 在两名同时患有不受控制的全身性疾病的患者中,没有实现长期缓解.
结论:
- 在这组耐火性疾病患者中,secukinumab 证明未能预防紫外炎发作.
- 需要进行额外的研究,以确定secukinumab在前性脑膜炎治疗中的潜在效用.
相关概念视频
Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...


